The Eindhoven startup VivArt-X collaborates with Maastricht UMC+ (MUMC+), Eindhoven University of Technology (TU/e) and Maastricht University (UM) to fast-track the developments of biomaterials for healthy breast tissue regeneration over the next three years. An amount of 3 million has been reserved for the project. Fifty percent of the costs are borne by the collaborating partners. Thirty-five percent comes from the European subsidy program OPZuid. The Provinces of Noord-Brabant and Limburg account for the remaining co-finance.

The research conducted by VivArt-X and its consortium partners has the potential to make a significant impact on public health. Breast cancer affects one in seven women during her lifetime, and more than 50 percent of patients require surgical removal of breast tissue, often followed by reconstructive surgery. Current reconstruction options involve multiple interventions and lengthy recovery periods. VivArt-X is developing a personalized regenerative approach in which the patient’s own cells are supported by our product Femtura to restore and regenerate volumetric healthy breast tissue. This approach helps to reduce the need for reoperations, shorten recovery time, and ultimately improve long-term quality of life for breast cancer patients.